AI-generated summary
This review examines the current evidence on the efficacy and safety of repeated low-level red-light therapy as a treatment to control myopia. The authors report that most research so far, mostly from China, suggests promising results, but long-term data on efficacy and safety remain limited. They call for further global research on this novel intervention.
- Who or what was studied
- People with myopia (nearsightedness), including children and those at risk of myopia progression
- Limits stated in the abstract
- Most available research comes from China and long-term efficacy and safety data are limited.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Myopia, Red light therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.